Integra Lifesciences Holdings (IART) Convertible Debt (2009 - 2024)

Integra Lifesciences Holdings (IART) has 13 years of Convertible Debt data on file, last reported at $571.7 million in Q2 2024.

• For the quarter ending Q2 2024, Convertible Debt rose 0.51% year-over-year to $571.7 million; the trailing twelve-month figure through Jun 2024 stood at $571.7 million (up 0.51% YoY), and the FY2023 full-year result was $570.3 million, up 0.51% from the prior year.
• Convertible Debt was little changed at $571.7 million in Q2 2024, from $571.0 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $571.7 million in Q2 2024 to a low of -$2.5 million in Q4 2020.
• A 5-year average of $518.3 million and a median of $565.5 million in 2022 frame the typical range for Convertible Debt.
• Across the five-year window, Convertible Debt surged 22677.04% in 2021 and advanced 0.51% in 2024, its largest moves.
• Tracing IART's Convertible Debt over 5 years: stood at -$2.5 million in 2020, then surged by 22677.04% to $564.4 million in 2021, then gained by 0.52% to $567.3 million in 2022, then climbed by 0.51% to $570.3 million in 2023, then rose by 0.26% to $571.7 million in 2024.
• Business Quant data shows IART's Convertible Debt at $571.7 million in Q2 2024, $571.0 million in Q1 2024, and $570.3 million in Q4 2023.